AUS
NZ
UK
CA
USA
IND
Highlights
- CSL (CSL) has seen a 14.7% decline in 2025, opening discussion on long-term value
- Pro Medicus (PME) maintains growth, with impressive revenue and profit trends
- Investors may want to monitor both stocks amid movements in the ASX200
As the healthcare sector continues to evolve, two major players on the ASX200—CSL (ASX:CSL) and Pro Medicus (ASX:PME)—are drawing attention for very different reasons in 2025.
CSL, a global biotechnology firm, has built its reputation through consistent performance and dividend reliability. However, its share price has dipped 14.7% since the beginning of the year. The company operates through its CSL Behring, CSL Seqirus, and CSL Vifor segments, focusing on blood plasma therapies, influenza vaccines, and kidney care solutions.
Key financial metrics suggest CSL remains a fundamentally sound business. Its FY24 debt-to-equity ratio was 62.8%, indicating more equity than debt, while its five-year average dividend yield stood at 1.5%—a notable feature for those interested in exploring reliable ASX dividend stocks. Additionally, CSL reported a return on equity (ROE) of 14.6% in FY24, exceeding the 10% benchmark that’s often considered a strong performance indicator for mature businesses.
Meanwhile, Pro Medicus is garnering attention for its tech-forward approach to medical imaging. Founded in 1983, the company has developed the Visage software suite—allowing radiologists to review high-resolution images on mobile devices, improving accessibility and decision-making speed.
Unlike CSL, Pro Medicus has remained within 18% of its 52-week high. As a growth-focused company, its numbers are telling. Revenue surged by 33.4% annually over the past three years, hitting $162 million in FY24. Net profit also climbed from $31 million to $83 million, while ROE reached an impressive 50.7%, highlighting efficient capital use.
These contrasting performances illustrate how companies at different growth stages can offer diverse opportunities within the same sector. CSL, considered one of the more stable ASX300 names, may appeal to those following blue-chip healthcare, while Pro Medicus shows momentum characteristic of high-growth tech-health hybrids.
With both stocks showing unique strengths in the healthcare space, they remain noteworthy for ongoing tracking as the ASX200 evolves in 2025.
